The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen
| Autor: | Sung Kyu Park, Sung Il Park, Weung Feel Park, Young Ik Lee, Eun Hwa Kang, Tae Young Kown, Goo Taeg Oh |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Hepatitis B virus
T-Lymphocytes viruses medicine.medical_treatment Mice Transgenic Biology Lymphocyte Activation medicine.disease_cause Immune tolerance Interferon-gamma Mice chemistry.chemical_compound Ellagic Acid Virology Immune Tolerance medicine Animals Immunologic Factors Cytotoxic T cell Hepatitis B e Antigens Hepatitis B Antibodies Cells Cultured Pharmacology B-Lymphocytes Plants Medicinal virus diseases Cytotoxicity Tests Immunologic digestive system diseases CTL Cytokine chemistry HBeAg Immunology biology.protein Interleukin-4 Antibody T-Lymphocytes Cytotoxic Ellagic acid |
| Zdroj: | Antiviral Research. 72:100-106 |
| ISSN: | 0166-3542 |
| DOI: | 10.1016/j.antiviral.2006.04.006 |
| Popis: | The aim of this study is to characterize the role of ellagic acid, a flavonoid from a medicinal herb which blocks HBeAg secretion in a HBV infected cell line and in HBeAg transgenic mice, in immune tolerance in chronic HBV infection. Using the mouse strain C57ML/6, HBeAg-producing transgenic mice (HBeAg-Tg), under the control of metal ion-inducible promoter were generated. The effect on immune tolerance of HBeAg-Tg and the release of immune tolerance by the inhibitor of HBeAg secretion, ellagic acid, was tested using T/B cell proliferation, HBeAg/HBeAb production, cytotoxic T-lymphocyte (CTL) and cytokine assays. C57ML/6 based HBeAg-producing HBeAg-Tg mice were tolerant to HBeAg at the T and B-cell level, did not produce antibodies to HBeAg in vivo and in vitro, produced minimal levels of cytokines (IL-4 and IFN-gamma) and decreased CTL responses, while feeding mice with ellagic acid (5mg/kg body weight) blocked the immune tolerance caused by HBeAg. Our results suggest that host immune tolerance induced by HBeAg during HBV infection, a viral strategy to guarantee HBV infection, can be overcome by ellagic acid, thus it can be used as a therapeutic for HBV-carriers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect